Skip to content

Pharminent

cropped-banner_frontpage_2026-07-11-2.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Commercial
  • Lilly’s Foundayo reaches 1,390 patients in first week, trailing Novo’s oral Wegovy launch
  • Commercial

Lilly’s Foundayo reaches 1,390 patients in first week, trailing Novo’s oral Wegovy launch

BioSpace

While Novo Nordisk's Wegovy pill reached more than 3,000 patients in its first week on the market, analysts at RBC Capital Markets said a direct comparison of the two figures could be misleading given

CommercialMetabolic & GLP-1Read full story

pharminent April 17, 2026 (Last updated: April 17, 2026)

BioSpace

While Novo Nordisk’s Wegovy pill reached more than 3,000 patients in its first week on the market, analysts at RBC Capital Markets said a direct comparison of the two figures could be misleading given

CommercialMetabolic & GLP-1Read full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: Obesity biotech Kailera’s record-breaking IPO
Next: Lilly’s obesity pill off to a strong start; OpenAI debuts new drug discovery tool

Related Stories

  • Commercial

Wegovy pill launches in UK as first daily oral GLP1 for weight management

pharminent July 6, 2026
  • Commercial

Tryngolza charts blockbuster course after FDA’s hypertriglyceridemia approval

pharminent June 26, 2026
  • Commercial

Lilly launches its LillyDirect sales channel in the UK

pharminent June 25, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.